Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors

Gastroenterology

Volumn 147, Issue 2, 2014, Pages

  McGivern, David R ^a   Masaki, Takahiro ^a   Williford, Sara ^a   Ingravallo, Paul ^b   Feng, Zongdi ^a   Lahser, Frederick ^b   Asante Appiah, Ernest ^b   Neddermann, Petra ^c   De Francesco, Raffaele ^c   Howe, Anita Y ^b   Lemon, Stanley M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Istituto Nazionale di Genetica Molecolare   (Italy)

Author keywords

Antiviral Agent; Replication; RNA Dependent RNA Polymerase; Therapy

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; LEDIPASVIR; NESBUVIR; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5A INHIBITOR; POLYPROTEIN; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA REPLICATION; RNA SYNTHESIS; VIRION; VIRUS ASSEMBLY; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS RELEASE;

ANTIVIRAL AGENT; REPLICATION; RNA-DEPENDENT RNA POLYMERASE; THERAPY;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; GENOTYPE; HEPACIVIRUS; HUMANS; KINETICS; MUTATION; PROTEASE INHIBITORS; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 84904730378     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.04.021     Document Type: Article

References (40)

1. C.M. Lange, I.M. Jacobson, and C.M. Rice et al. Emerging therapies for the treatment of hepatitis C EMBO Mol Med 1 2013 4 15
2. W.P. Hofmann, and S. Zeuzem A new standard of care for the treatment of chronic HCV infection Nat Rev Gastroenterol Hepatol 8 2011 257 264
3. M. Gao, R.E. Nettles, and M. Belema et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
4. I. Conte, C. Giuliano, and C. Ercolani et al. Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture Bioorg Med Chem Lett 19 2009 1779 1783
5. J.A. Lemm, D. O'Boyle 2nd, and M. Liu et al. Identification of hepatitis C virus NS5A inhibitors J Virol 84 2010 482 491
6. D.R. O'Boyle Ii, J.H. Sun, and P.T. Nower et al. Characterizations of HCV NS5A replication complex inhibitors Virology 444 2013 343 354
7. A. Milward, J. Mankouri, and M. Harris Hepatitis C virus NS5A protein interacts with beta-catenin and stimulates its transcriptional activity in a phosphoinositide-3 kinase-dependent fashion J Gen Virol 91 2010 373 381
8. K.L. Lemay, J. Treadaway, and I. Angulo et al. A hepatitis C virus NS5A phosphorylation site that regulates RNA replication J Virol 87 2013 1255 1260
9. M. Bobardt, S. Hopkins, and J. Baugh et al. HCV NS5A and IRF9 compete for CypA binding J Hepatol 58 2013 16 23
10. Y. Miyanari, K. Atsuzawa, and N. Usuda et al. The lipid droplet is an important organelle for hepatitis C virus production Nat Cell Biol 9 2007 1089 1097
11. J.O. Link, J.G. Taylor, and L. Xu et al. The discovery of ledipasvir (GS-5885), a potent once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection J Med Chem 57 2013 2033 2046
12. C.A. Coburn, P.T. Meinke, and W. Chang et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity Chem Med Chem 8 2013 1930 1940
13. A.S. Lok, D.F. Gardiner, and E. Lawitz et al. Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
14. F. McPhee, D. Hernandez, and F. Yu et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir Hepatology 58 2013 902 911
15. J. Guedj, H. Dahari, and L. Rong et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Proc Natl Acad Sci U S A 110 2013 3991 3996
16. T. Shimakami, C. Welsch, and D. Yamane et al. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus Gastroenterology 140 2011 667 675
17. R.P. Kannan, L.L. Hensley, and L.E. Evers et al. Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis J Virol 85 2011 7989 8001
18. E.J. Lawitz, D. Gruener, and J.M. Hill et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C J Hepatol 57 2012 24 31
19. B.A. Malcolm, R. Liu, and F. Lahser et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells Antimicrob Agents Chemother 50 2006 1013 1020
20. N.J. Liverton, S.S. Carroll, and J. Dimuzio et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease Antimicrob Agents Chemother 54 2010 305 311
21. S.S. Carroll, S. Ludmerer, and L. Handt et al. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees Antimicrob Agents Chemother 53 2009 926 934
22. A.Y. Howe, H. Cheng, and S. Johann et al. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796 Antimicrob Agents Chemother 52 2008 3327 3338
23. P. Targett-Adams, E.J. Graham, and J. Middleton et al. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action J Virol 85 2011 6353 6368
24. R.A. Fridell, D. Qiu, and C. Wang et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system Antimicrob Agents Chemother 54 2010 3641 3650
25. R.A. Fridell, C. Wang, and J.H. Sun et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations Hepatology 54 2011 1924 1935
26. T.L. Tellinghuisen, K.L. Foss, and J. Treadaway Regulation of hepatitis C virion production via phosphorylation of the NS5A protein PLoS Pathog 4 2008 e1000032
27. S. Kim, C. Welsch, and M. Yi et al. Regulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain III J Virol 85 2011 6645 6656
28. D. Qiu, J.A. Lemm, and D.R. O'Boyle 2nd et al. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization J Gen Virol 92 2011 2502 2511
29. S. Reiss, C. Harak, and I. Romero-Brey et al. The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A PLoS Pathog 9 2013 e1003359
30. A.L. Leivers, M. Tallant, and J.B. Shotwell et al. Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIalpha) inhibitors as anti hepatitis C (HCV) agents J Med Chem 57 2013 2091 2106
31. N. Appel, M. Zayas, and S. Miller et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly PLoS Pathog 4 2008 e1000035
32. C. Lee, H. Ma, and J.Q. Hang et al. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein Virology 414 2011 10 18
33. B. Wolk, B. Buchele, and D. Moradpour et al. A dynamic view of hepatitis C virus replication complexes J Virol 82 2008 10519 10531
34. K.L. Berger, J.D. Cooper, and N.S. Heaton et al. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication Proc Natl Acad Sci U S A 106 2009 7577 7582
35. K.L. Berger, S.M. Kelly, and T.X. Jordan et al. Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication J Virol 85 2011 8870 8883
36. Y. Ma, J. Yates, and Y. Liang et al. NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly J Virol 82 2008 7624 7639
37. T. Shimakami, C. Welsch, and D. Yamane et al. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus Gastroenterology 140 2011 667 675
38. P. Gastaminza, S.B. Kapadia, and F.V. Chisari Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles J Virol 80 2006 11074 11081
39. B.A. Malcolm, R. Liu, and F. Lahser et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells Antimicrob Agents Chemother 50 2006 1013 1020
40. T. Shimakami, D. Yamane, and R.K. Jangra et al. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex Proc Natl Acad Sci U S A 109 2012 941 946